309 related articles for article (PubMed ID: 35124126)
1. Nanoparticle-based delivery strategies of multifaceted immunomodulatory RNA for cancer immunotherapy.
Yoo YJ; Lee CH; Park SH; Lim YT
J Control Release; 2022 Mar; 343():564-583. PubMed ID: 35124126
[TBL] [Abstract][Full Text] [Related]
2. Chemical Strategies to Enhance the Therapeutic Efficacy of Toll-like Receptor Agonist Based Cancer Immunotherapy.
Lee SN; Jin SM; Shin HS; Lim YT
Acc Chem Res; 2020 Oct; 53(10):2081-2093. PubMed ID: 32966047
[TBL] [Abstract][Full Text] [Related]
3. Nanotechnology-Based siRNA Delivery Systems to Overcome Tumor Immune Evasion in Cancer Immunotherapy.
Deng K; Yang D; Zhou Y
Pharmaceutics; 2022 Jun; 14(7):. PubMed ID: 35890239
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle Retinoic Acid-Inducible Gene I Agonist for Cancer Immunotherapy.
Wang-Bishop L; Wehbe M; Pastora LE; Yang J; Kimmel BR; Garland KM; Becker KW; Carson CS; Roth EW; Gibson-Corley KN; Ulkoski D; Krishnamurthy V; Fedorova O; Richmond A; Pyle AM; Wilson JT
ACS Nano; 2024 May; 18(18):11631-11643. PubMed ID: 38652829
[TBL] [Abstract][Full Text] [Related]
5. Emerging Nanoparticle Strategies for Modulating Tumor-Associated Macrophage Polarization.
Shi L; Gu H
Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944555
[TBL] [Abstract][Full Text] [Related]
6. Delivery of 5'-triphosphate RNA with endosomolytic nanoparticles potently activates RIG-I to improve cancer immunotherapy.
Jacobson ME; Wang-Bishop L; Becker KW; Wilson JT
Biomater Sci; 2019 Jan; 7(2):547-559. PubMed ID: 30379158
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticle mediated cancer immunotherapy.
Gupta J; Safdari HA; Hoque M
Semin Cancer Biol; 2021 Feb; 69():307-324. PubMed ID: 32259643
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticles for nucleic acid delivery: Applications in cancer immunotherapy.
Mukalel AJ; Riley RS; Zhang R; Mitchell MJ
Cancer Lett; 2019 Aug; 458():102-112. PubMed ID: 31100411
[TBL] [Abstract][Full Text] [Related]
9. Insight into RNA-based Therapies for Ovarian Cancer.
Keyvani V; Mahmoudian RA; Mollazadeh S; Kheradmand N; Ghorbani E; Khazaei M; Saeed Al-Hayawi I; Hassanian SM; Ferns GA; Avan A; Anvari K
Curr Pharm Des; 2023; 29(34):2692-2701. PubMed ID: 37916491
[TBL] [Abstract][Full Text] [Related]
10. RNA Nanotechnology-Mediated Cancer Immunotherapy.
Lin YX; Wang Y; Blake S; Yu M; Mei L; Wang H; Shi J
Theranostics; 2020; 10(1):281-299. PubMed ID: 31903120
[TBL] [Abstract][Full Text] [Related]
11. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.
Gong C; Yu X; Zhang W; Han L; Wang R; Wang Y; Gao S; Yuan Y
J Nanobiotechnology; 2021 Feb; 19(1):58. PubMed ID: 33632231
[TBL] [Abstract][Full Text] [Related]
12. TRAIL-modified, doxorubicin-embedded periodic mesoporous organosilica nanoparticles for targeted drug delivery and efficient antitumor immunotherapy.
Feng X; Li F; Zhang L; Liu W; Wang X; Zhu R; Qiao ZA; Yu B; Yu X
Acta Biomater; 2022 Apr; 143():392-405. PubMed ID: 35259519
[TBL] [Abstract][Full Text] [Related]
13. Hydrophobization of Ribonucleic Acids for Facile Systemic Delivery and Multifaceted Cancer Immunotherapy.
Zhang Y; Chen C; Su M; Wang J; Li C; Yang X
Nano Lett; 2024 Jan; 24(4):1376-1384. PubMed ID: 38232332
[TBL] [Abstract][Full Text] [Related]
14. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
Varshosaz J; Farzan M
World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
[TBL] [Abstract][Full Text] [Related]
15. Smart Nanoparticle-Based Platforms for Regulating Tumor Microenvironment and Cancer Immunotherapy.
Cheng R; Santos HA
Adv Healthc Mater; 2023 Mar; 12(8):e2202063. PubMed ID: 36479842
[TBL] [Abstract][Full Text] [Related]
16. Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages.
Qian Y; Qiao S; Dai Y; Xu G; Dai B; Lu L; Yu X; Luo Q; Zhang Z
ACS Nano; 2017 Sep; 11(9):9536-9549. PubMed ID: 28858473
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy.
Miele E; Spinelli GP; Miele E; Di Fabrizio E; Ferretti E; Tomao S; Gulino A
Int J Nanomedicine; 2012; 7():3637-57. PubMed ID: 22915840
[TBL] [Abstract][Full Text] [Related]
18. Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy.
Phuengkham H; Ren L; Shin IW; Lim YT
Adv Mater; 2019 Aug; 31(34):e1803322. PubMed ID: 30773696
[TBL] [Abstract][Full Text] [Related]
19. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.
Song Y; Tang C; Yin C
Biomaterials; 2018 Dec; 185():117-132. PubMed ID: 30241030
[TBL] [Abstract][Full Text] [Related]
20. Improving the therapeutic efficiency of noncoding RNAs in cancers using targeted drug delivery systems.
Alzhrani R; Alsaab HO; Petrovici A; Bhise K; Vanamala K; Sau S; Krinock MJ; Iyer AK
Drug Discov Today; 2020 Apr; 25(4):718-730. PubMed ID: 31758914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
